Concepedia

Howard L. Kaufman

HL

Statistics

Publications

5

Citations

3.2K

H-Index

5

Active since

2002

Affiliations

Amgen (United States)(Current)

Amgen (United Kingdom)

Huntsman Cancer Institute

Rutgers Cancer Institute

Rutgers, The State University of New Jersey

Howard L. Kaufman is an author at Amgen (United States).

Publications per year

2002–2019

5

Publications

5

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.5K citations · Full text

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Robert H.I. Andtbacka, Frances A. Collichio, Kevin J. Harrington et al. · Journal for ImmunoTherapy of Cancer · 2019 · 413 citations · Full text

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

Kevin J. Harrington, Robert H.I. Andtbacka, Frances A. Collichio et al. · OncoTargets and Therapy · 2016 · 99 citations · Full text

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Howard L. Kaufman, Thomas Amatruda, Tony Reid et al. · Journal for ImmunoTherapy of Cancer · 2016 · 96 citations · Full text

Uterine rupture with the use of PGE2 vaginal inserts for labor induction in women with previous cesarean sections.

Donald R. Taylor, Andrea Doughty, Howard L. Kaufman et al. · PubMed · 2002 · 37 citations

Rows per page

1–5 of 5